Overview

A class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ : IBRX) and the Company’s Chief Executive Officer (“CEO”) (collectively, “Defendants”), alleging violations of the federal securities laws. The ImmunityBio lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired ImmunityBio securities between January 19, 2026, and March 24, 2026, both dates inclusive (the “Class Period”). Investors have until May 26, 2026, to seek appointment as lead plaintiff of the ImmunityBio class action lawsuit.

ImmunityBio is a biotechnology company. The complaint alleges that Defendants made materially false and misleading statements regarding the capabilities and efficacy of its lead product, ANKTIVA. Specifically, Defendants promoted ANKTIVA as a potential cure for multiple cancers, a cancer vaccine, and a therapy capable of preventing cancer.

According to the complaint, these statements overstated ANKTIVA’s clinical effectiveness and misrepresented its approved uses, which are limited to certain forms of bladder cancer. The Company also failed to disclose that ANKTIVA had not been proven effective as a standalone treatment and was not approved for the broad indications suggested in promotional materials.

The truth emerged on March 24, 2026, when the U.S. Food and Drug Administration (“FDA”) issued a Warning Letter finding that certain of ImmunityBio’s promotional statements were misleading and improperly suggested unapproved uses of ANKTIVA. The FDA emphasized that the drug had not been shown to cure or prevent cancer and criticized the Company for misbranding and unsupported efficacy claims. Notably, the Warning Letter stated: “The consistent and pervasive misleading efficacy claims and representations presented across promotional materials on different platforms are especially concerning from a public health perspective, given that they grossly misrepresent the benefits of Anktiva. We are not aware of data that would support [Defendants’] claims and representations.”

On this news, ImmunityBio stock fell $1.98 per share, or 21%, to close at $7.42 per share on March 24, 2026.

*          *          *

If you purchased or otherwise acquired ImmunityBio securities between January 19, 2026, and March 24, 2026, and you wish to serve as lead plaintiff in this lawsuit, you are encouraged to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt attorneys Brian O’Mara and Hani Farah by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as a lead plaintiff in the ImmunityBio class action lawsuit is May 26, 2026.